Savara Inc. Securities Fraud Investigation

Shamis & Gentile, P.A. announces that a securities class action lawsuit has been filed against Savara Inc. ("Savara" or the "Company") (SVRA) concerning alleged violations of federal securities laws during the period from March 7, 2024 to May 23, 2025.

Investors who purchased Savara securities during the class period may be eligible to serve as lead plaintiff. The deadline to apply to be lead plaintiff is approaching. Contact Shamis & Gentile now to learn more about your rights and potential recovery.

The complaint alleges that Savara made materially false and misleading statements and failed to disclose critical information to investors regarding the development and regulatory status of its lead product candidate, molgramostim, for the treatment of autoimmune pulmonary alveolar proteinosis (aPAP). According to the lawsuit, throughout the class period, Savara repeatedly assured investors that the IMPALA-2 Phase 3 clinical trial was progressing as planned and that the Company was on track to submit a Biologics License Application (BLA) to the U.S. Food and Drug Administration. Plaintiffs allege that these statements were materially misleading because Savara failed to disclose significant adverse data from the trial, including a higher-than-expected rate of serious adverse events and questions regarding the trial's primary endpoint.

The lawsuit claims that, as a result of these omissions and misrepresentations, Savara's stock traded at artificially inflated prices during the class period. The complaint further alleges that Savara violated Sections 10(b) and 20(a) of the Securities Exchange Act of 1934 and SEC Rule 10b-5 by disseminating false and misleading statements and failing to disclose material adverse facts about the Company's business, operations and prospects. Plaintiffs allege that when the true facts were revealed, investors suffered significant losses.

According to the complaint, the truth emerged on May 23, 2025, when Savara disclosed in a press release that the IMPALA-2 trial failed to meet its primary endpoint and that the Company would not proceed with a BLA submission for molgramostim. On this news, shares of Savara fell $3.75 per share, or approximately 42 percent, closing at $5.15 per share on May 23, 2025. This decline erased over $200 million in market capitalization and caused substantial financial harm to investors.

Investors with significant losses in Savara securities are encouraged to contact Shamis & Gentile, P.A. today for more information about the lawsuit, your rights or how to serve as lead plaintiff. There is no cost or obligation to investigate your claim.

Shamis & Gentile, P.A. stands out as an advocate for investors who are victims of securities fraud. The firm is committed to securing recoveries for investors who have incurred damages due to false and misleading statements or other corporate misconduct by public companies. Shamis & Gentile has recovered over $1 billion for consumers nationwide. Its extensive experience, expertise and resources enable the firm to resolve disputes in a wide range of matters, including class actions, mass torts and mass arbitrations.

Attorney advertising. Prior results do not guarantee similar outcomes.